Syndax Pharmaceuticals SNDX Income Statement (2015-2026)

NASDAQ SNDX
$9.49 -0.06 (-0.63%)
At close: Nov 10, 2026 · 4:00 PM EST
Reported Financials

Syndax Pharmaceuticals Quarterly Income Statement

Periods 47 quarters
Latest Sep 2026

Syndax Pharmaceuticals reported revenue of $83.30M and net income of -$36.30M for the quarter ended Sep 2026, up 81.6% year over year. This income statement covers 47 quarters of results from Mar 2015 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
126.58M3.50M12.50M7.68M20.04M37.96M45.87M68.73M64.86M72.79M83.30M
Cost of RevenueCost of Rev
0.83M0.89M1.28M2.10M2.71M2.63M3.21M14.00M
Gross Profit
3.50M12.50M6.85M19.16M36.68M43.77M66.02M62.23M69.58M69.30M
Operating items
Research & DevelopmentR&D
23.90M30.02M29.73M26.90M31.84M34.05M34.76M39.09M55.13M56.49M48.66M70.97M65.53M61.64M62.23M56.28M78.64M58.85M68.04M67.48M
Selling, General & AdministrativeSG&A
6.93M6.84M7.99M8.24M10.19M11.96M14.91M17.27M22.78M23.02M29.06M31.11M37.69M41.03M43.81M44.92M49.93M37.59M41.54M43.72M
Other Operating ExpensesOther Opex
4.93M8.30M7.85M8.28M9.59M11.85M12.12M11.81M
Operating ExpensesOpex
30.83M36.86M37.72M35.14M42.03M46.02M49.68M56.36M77.91M79.51M77.72M102.08M104.05M103.80M107.31M103.30M131.28M99.07M112.78M125.19M
Operating IncomeOp. Inc
95.75M-36.86M-37.72M-35.14M-42.03M-46.02M-49.68M-56.36M-77.91M-79.51M-74.22M-89.58M-96.37M-83.76M-69.35M-57.43M-62.55M-34.20M-40.00M-41.90M
Non-operating items
Non Operating Interest Expenses
-0.01M0.65M0.70M1.75M0.04M0.04M0.04M0.07M0.06M0.06M0.05M0.02M-0.12M0.00M0.00M0.00M0.00M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.69M-0.70M-0.27M0.47M-0.24M0.12M-0.97M-0.06M1.19M0.36M-0.24M0.24M-0.44M-0.15M-1.53M
Interest & Investment IncomeInt & Inv Inc
0.09M0.22M0.88M1.78M2.99M5.08M5.19M5.35M5.55M7.26M6.28M5.44M7.11M7.18M5.95M5.27M4.33M3.56M3.75M5.59M
Other Non Operating IncomeOther Non Op Inc.
0.35M0.12M-0.03M-0.30M-0.11M-0.15M-0.09M-0.07M-0.06M0.09M0.09M0.03M-0.11M-0.22M-0.59M-0.28M-0.20M-0.19M-0.44M-0.15M
Non Operating IncomeNon Op. Inc.
0.45M-0.31M0.15M0.26M2.84M4.89M5.06M5.21M5.43M7.11M6.15M5.45M2.20M-1.09M-2.49M-3.29M-5.47M-8.47M-9.37M-7.54M
Net income details
EBIT
95.75M-36.86M-37.72M-35.14M-42.03M-46.02M-49.68M-56.36M-77.91M-79.51M-74.22M-89.58M-96.37M-83.76M-69.35M-57.43M-62.55M-34.20M-40.00M-41.90M
EBT
95.85M-37.29M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.31M-67.98M-82.94M-89.13M-76.58M-63.41M-60.48M-58.22M-30.64M-36.25M-36.30M
Income After Tax
95.85M-37.29M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.31M-67.98M-82.94M-89.13M-76.58M-63.41M-60.48M-58.22M-30.64M-36.25M-36.30M
Income from Continuing OperationsIncome (Continuing)
95.85M-37.29M-37.54M-35.11M-39.09M-40.98M-44.52M-51.08M-72.42M-72.31M-67.98M-82.94M-89.13M-76.58M-63.41M-60.48M-58.22M-30.64M-36.25M-36.30M
Consolidated Net IncomeConsol Net Inc.
95.85M-37.85M-38.27M-35.67M-39.09M-40.66M-44.85M-51.03M-72.42M-73.37M-68.12M-82.94M-89.13M-76.58M-63.41M-60.48M-58.22M-30.64M-36.25M-36.30M
Income towards Parent CompanyParent Net Inc
96.20M-37.17M-37.57M-35.40M-39.19M-41.13M-44.62M-51.15M-72.47M-72.40M-68.06M-84.13M-94.17M-84.85M-71.85M-60.72M-68.01M-42.67M-49.36M-49.43M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
96.20M-37.17M-37.57M-35.40M-39.19M-41.13M-44.62M-51.15M-72.47M-72.40M-68.06M-84.13M-94.17M-84.85M-71.85M-60.72M-68.01M-42.67M-49.36M-49.43M
Additional items
EPS (Basic)
1.85-0.63-0.62-0.58-0.65-0.59-0.64-0.73-1.03-0.85-0.80-0.98-1.10-0.98-0.83-0.70-0.79-0.48-0.55-0.55
EPS (Diluted)
1.79-0.63-0.62-0.58-0.65-0.59-0.64-0.73-1.03-0.85-0.80-0.98-1.10-0.98-0.83-0.70-0.79-0.48-0.55-0.55
Shares Outstanding
52.07M58.98M60.16M60.67M60.76M69.44M69.64M69.86M70.37M85.21M85.27M85.43M85.62M86.17M86.34M86.62M86.63M88.26M88.99M89.79M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
53.62M58.98M60.16M60.67M60.76M69.44M69.64M69.86M70.37M85.21M85.27M85.43M85.62M86.17M86.34M86.62M86.63M88.26M88.99M89.79M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
54.98M55.03M56.40M60.12M68.11M68.50M69.43M69.64M70.37M84.98M85.03M85.57M85.69M86.05M86.06M86.91M87.41M88.54M89.15M89.99M
EBITDA
95.76M-36.85M-37.71M-35.13M-42.03M-46.01M-49.68M-56.35M-77.90M-79.51M-74.21M-89.58M-88.34M-83.65M-69.30M-54.36M-59.55M-30.15M-34.69M-35.72M
Interest ExpensesInt Expense
-0.01M0.65M0.70M1.75M0.04M0.04M0.04M0.07M0.06M0.06M0.05M0.02M-0.12M0.00M0.00M0.00M0.00M

Syndax Pharmaceuticals Income Statement API

Pull Syndax Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SNDX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY